Show simple item record

dc.contributor.authorRawool, Deepak B.
dc.contributor.authorBitsaktsis, Constantine
dc.contributor.authorLi, Ying
dc.contributor.authorGosselin, Diane R.
dc.contributor.authorLin, Yili
dc.contributor.authorKurkure, Nitin V.
dc.contributor.authorMetzger, Dennis W.
dc.contributor.authorGosselin, Edmund J.
dc.date2022-08-11T08:08:52.000
dc.date.accessioned2022-08-23T16:10:24Z
dc.date.available2022-08-23T16:10:24Z
dc.date.issued2008-04-09
dc.date.submitted2009-02-23
dc.identifier.citation<p>J Immunol. 2008 Apr 15;180(8):5548-57.</p>
dc.identifier.issn0022-1767 (Print)
dc.identifier.doi10.4049/jimmunol.180.8.5548
dc.identifier.pmid18390739
dc.identifier.urihttp://hdl.handle.net/20.500.14038/32924
dc.description.abstractNumerous studies have demonstrated that targeting Ag to Fc receptors (FcR) on APCs can enhance humoral and cellular immunity. However, studies are lacking that examine both the use of FcR-targeting in generating immune protection against infectious agents and the use of FcRs in the induction of mucosal immunity. Francisella tularensis is a category A intracellular mucosal pathogen. Thus, intense efforts are underway to develop a vaccine against this organism. We hypothesized that protection against mucosal infection with F. tularensis would be significantly enhanced by targeting inactivated F. tularensis live vaccine strain (iFt) to FcRs at mucosal sites, via intranasal immunization with mAb-iFt complexes. These studies demonstrate for the first time that: 1) FcR-targeted immunogen enhances immunogen-specific IgA production and protection against subsequent infection in an IgA-dependent manner, 2) FcgammaR and neonatal FcR are crucial to this protection, and 3) inactivated F. tularensis, when targeted to FcRs, enhances protection against the highly virulent SchuS4 strain of F. tularensis, a category A biothreat agent. In summary, these studies show for the first time the use of FcRs as a highly effective vaccination strategy against a highly virulent mucosal intracellular pathogen.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=18390739&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787710/
dc.subjectAdministration, Intranasal; Animals; Antibodies, Bacterial; Bacterial Vaccines; Cytokines; Francisella tularensis; Immunity, Mucosal; Immunization, Secondary; Immunoglobulin A; Immunologic Memory; Inflammation; Interferon-gamma; Liver; Lung; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mucous Membrane; Receptors, Fc; Spleen; Tularemia; Vaccination
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleUtilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis
dc.typeJournal Article
dc.source.journaltitleJournal of immunology (Baltimore, Md. : 1950)
dc.source.volume180
dc.source.issue8
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/gsbs_sp/1475
dc.identifier.contextkey733772
html.description.abstract<p>Numerous studies have demonstrated that targeting Ag to Fc receptors (FcR) on APCs can enhance humoral and cellular immunity. However, studies are lacking that examine both the use of FcR-targeting in generating immune protection against infectious agents and the use of FcRs in the induction of mucosal immunity. Francisella tularensis is a category A intracellular mucosal pathogen. Thus, intense efforts are underway to develop a vaccine against this organism. We hypothesized that protection against mucosal infection with F. tularensis would be significantly enhanced by targeting inactivated F. tularensis live vaccine strain (iFt) to FcRs at mucosal sites, via intranasal immunization with mAb-iFt complexes. These studies demonstrate for the first time that: 1) FcR-targeted immunogen enhances immunogen-specific IgA production and protection against subsequent infection in an IgA-dependent manner, 2) FcgammaR and neonatal FcR are crucial to this protection, and 3) inactivated F. tularensis, when targeted to FcRs, enhances protection against the highly virulent SchuS4 strain of F. tularensis, a category A biothreat agent. In summary, these studies show for the first time the use of FcRs as a highly effective vaccination strategy against a highly virulent mucosal intracellular pathogen.</p>
dc.identifier.submissionpathgsbs_sp/1475
dc.contributor.departmentProgram in Immunology and Virology
dc.contributor.departmentGraduate School of Biomedical Sciences
dc.source.pages5548-57


This item appears in the following Collection(s)

Show simple item record